

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>SVLSF VI, LLC</u> (Last) (First) (Middle) ONE BOSTON PLACE, SUITE 3900 201 WASHINGTON STREET (Street) BOSTON MA 02108 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>AVROBIO, Inc. [AVRO]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>01/16/2019</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/16/2019		J ⁽¹⁾		778,663	D	\$0.00	1,866,791	I	See Footnote ⁽²⁾
Common Stock	01/16/2019		J ⁽³⁾		26,660	D	\$0.00	63,913	I	See Footnote ⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person* <u>SVLSF VI, LLC</u> (Last) (First) (Middle) ONE BOSTON PLACE, SUITE 3900 201 WASHINGTON STREET (Street) BOSTON MA 02108 (City) (State) (Zip)

1. Name and Address of Reporting Person*		
SV Life Sciences Fund VI, L.P.		
(Last)	(First)	(Middle)
ONE BOSTON PLACE, SUITE 3900 201 WASHINGTON STREET		
(Street)		
BOSTON	MA	02108
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
SV Life Sciences Fund VI Strategic Partners, L.P.		
(Last)	(First)	(Middle)
ONE BOSTON PLACE, SUITE 3900 201 WASHINGTON STREET		
(Street)		
BOSTON	MA	02108
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
SV Life Sciences Fund VI (GP), L.P.		
(Last)	(First)	(Middle)
ONE BOSTON PLACE, SUITE 3900 201 WASHINGTON STREET		
(Street)		
BOSTON	MA	02108
(City)	(State)	(Zip)

Explanation of Responses:

- SV Life Sciences Fund VI, L.P. ("SV Life LP") distributed the shares to its limited partners on a pro rata basis.
- The shares are held directly by SV Life LP. SV Life Sciences Fund VI (GP), L.P. ("SV Fund VI GP") is the general partner of SV Life LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. Each of SV Fund VI GP and SVLSF VI, LLC disclaims beneficial ownership of the shares owned directly by SV Life LP, except to the extent of any pecuniary interest therein.
- SV Life Sciences Fund VI Strategic Partners, L.P. ("SV Life SP LP") distributed the shares to its limited partners on a pro rata basis.
- The shares are held directly by SV Life SP LP. SV Fund VI GP is the general partner of SV Life SP LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. Each of SV Fund VI GP, and SVLSF VI, LLC disclaims beneficial ownership of the shares owned directly by SV Life SP LP, except to the extent of any pecuniary interest therein.

Remarks:

[SV Life Sciences Fund VI, L.P., By: SV Life Sciences Fund VI \(GP\), L.P., Its: sole General Partner, By: SVLSF VI, LLC, Its: sole General Partner, By: Brent M. Faduski, Officer, /s/ Brent M. Faduski](#) 01/18/2019

[SV Life Sciences Fund VI Strategic Partners, L.P., By: SV Life Sciences Fund VI \(GP\), L.P., Its: sole General Partner, By: SVLSF VI, LLC, Its: sole General Partner, By: Brent M. Faduski, Officer, /s/ Brent M. Faduski](#) 01/18/2019

[SV Life Sciences Fund VI \(GP\), L.P., By: SVLSF VI, LLC, Its: sole General Partner, By: Brent M. Faduski, Officer, /s/ Brent M. Faduski](#) 01/18/2019

SVLSF VI, LLC, By: Brent M.
Faduski, Officer. /s/ Brent M. 01/18/2019
Faduski

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.